Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, Hawaii, USA.
Am J Hematol. 2021 Oct 1;96(10):1241-1252. doi: 10.1002/ajh.26292. Epub 2021 Jul 28.
Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD-TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper-vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD-TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD-TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword "TAFRO" to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD-TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD-TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co-morbidities), and (3) TAFRO without iMCD or other co-morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD-TAFRO.
血小板减少症、全身性水肿、发热、网状纤维纤维化、肾功能不全和器官肿大(TAFRO)综合征是一种异质性实体,表现为上述一系列症状,可发生在特发性多中心 Castleman 病(iMCD)以及传染病、恶性肿瘤和风湿性疾病的背景下。因此,iMCD-TAFRO 是 iMCD 的一种侵袭性亚型,具有 TAFRO 综合征和常伴有高血管化的淋巴结。自 2016 年我们提出 iMCD-TAFRO 的诊断标准以来,我们对该疾病有了新的认识,并且在全球范围内报告了更多的病例。在这项系统回顾和队列分析中,我们建立并验证了 iMCD-TAFRO 的定义。首先,我们使用“TAFRO”一词在 PubMed 和日本医学文摘协会数据库中进行搜索,以提取病例。排除可能患有系统性自身免疫性疾病和血液恶性肿瘤的患者。我们的搜索从 50 篇文章中确定了 54 例病例。我们将病例分为三类:(1)iMCD-TAFRO(具有符合 iMCD 的淋巴结组织病理学的 TAFRO 综合征),(2)可能的 iMCD-TAFRO(未进行淋巴结活检且无其他合并症的 TAFRO 综合征),和(3)无 iMCD 或其他合并症的 TAFRO(与 iMCD 或其他合并症不一致的淋巴结组织病理学的 TAFRO 综合征)。基于这些发现,我们提出了一个国际定义,需要四项临床标准(血小板减少症、全身性水肿、发热/炎症状态、器官肿大)、肾功能不全或特征性骨髓发现以及符合 iMCD 的淋巴结特征。该定义在一个外部队列(ACCELERATE 自然史登记处)中得到了验证。目前的国际定义将有助于更精确和全面地诊断 iMCD-TAFRO。